The theme for this year’s Black History Month is Black Health and Wellness. With Black History And Medicine AR experience, ROSE and 8th Wall created an AR timeline about this facet of US history.

Originally written by Will Fraser-Allen on Growth Business

Will Fraser-Allen, managing partner at Albion Capital, explains how venture capital trusts are driving growth in UK tech start-ups

According to the Research Institute for Cooking & Kitchen Intelligence’s latest poll, the top 10 most desired design features include numerous wellness-enhancing features.

TOKYO and KENILWORTH, N.J., Feb 25, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A., for radically unresectable or metastatic renal cell carcinoma (RCC). LENVIMA plus KEYTRUDA is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC. This marks the second approval of this combination in Japan; in December 2021, LENVIMA plus KEYTRUDA was approved for unresectable, advanced or recurrent endometrial carcinoma that progressed after chemotherapy. The approval is based on results from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, in which LENVIMA plus KEYTRUDA demonstrated statistically significant improvements versus sunitinib in the primary efficacy outcome measure of progression-free survival (PFS). Results showed LENVIMA plus KEYTRUDA (n=355) reduced the risk of disease progression or death by 61% (HR=0.39 [95% CI, 0.32-0.49]; p<0.0001), with a median PFS of 23.9 months versus 9.2 months for sunitinib (n=357).

"Nearly one in three cases of renal cell carcinoma are diagnosed at an advanced stage,(1) and patients are in need of new treatment options that may improve survival outcomes,(2)" said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck & Co., Inc., Kenilworth,

N.J., U.S.A. Research Laboratories. "In the CLEAR/KEYNOTE-581 trial, KEYTRUDA plus LENVIMA reduced the risk of disease progression or death by 61% versus sunitinib, a current standard of care. We are encouraged that patients with certain types of advanced renal cell carcinoma may have the opportunity to benefit from this combination."

"Today's milestone for LENVIMA plus KEYTRUDA as a treatment for radically unresectable or metastatic renal cell carcinoma is particularly exciting as it marks the second approval for the combination in Japan," said Terushige Iike, President of Eisai Japan, Senior Vice President, Eisai. "We are thrilled to be able to provide Japanese patients with a new treatment option, illustrating our shared commitment with Merck & Co., Inc., Kenilworth, N.J., U.S.A. to develop therapies with the aim of addressing the unmet needs of those living with difficult-to-treat cancers. We would like to thank the patients, families and healthcare providers who made this approval possible."

The Japanese package inserts for LENVIMA and KEYTRUDA note that in the CLEAR/KEYNOTE-581 trial, adverse reactions were observed in 341 (96.9%) of 352 patients (including 42 of 42 Japanese patients) in the safety analysis set. The most common adverse reactions included diarrhea in 192 patients (54.5%), hypertension in 184 patients (52.3%), hypothyroidism in 150 patients (42.6%), decreased appetite in 123 patients (34.9%), fatigue in 113 patients (32.1%), stomatitis in 113 patients (32.1%), palmar-plantar erythrodysesthesia syndrome in 99 patients (28.1%), proteinuria in 97 patients (27.6%), nausea in 94 patients (26.7%), dysphonia in 87 patients (24.7%), rash in 77 patients (21.9%), and asthenia in 71 patients (20.2%).

Renal cell carcinoma is the most common type of kidney cancer worldwide; about nine out of 10 kidney cancer diagnoses are RCC.(3) In Japan, there were more than 25,000 new cases of kidney cancer diagnosed and more than 8,000 deaths from the disease in 2020.(4) Approximately 30% of patients with RCC will have metastatic disease at diagnosis.(5) Survival is highly dependent on the stage at diagnosis, and with a five-year survival rate of 14% for patients diagnosed with metastatic disease, the prognosis for these patients is poor.(6)

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. continue to study the LENVIMA plus KEYTRUDA combination across several types of cancer with more than 20 clinical trials.

For more information, visit https://www.eisai.com/news/2022/pdf/enews202214pdf.pdf.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.

  More Scandal from Credit Suisse For poor Credit Suisse it seems that it never just rains but is a continual and extremely heavy downpour. This time it is an information leak published in both the Guardian and the New York Times which shines a light on some of  less than squeaky clean clients. On […]

The post Alt Lending week ending 25th February 2022 appeared first on Daily Fintech.

Mushrooms are becoming the next big thing, and that means more questions being asked. Like how to grow them? And if they mix well with weed. And whether or not you can smoke magic mushrooms. So, let’s take a look at that question today, and go over the different ways that magic mushrooms can be […]

The post Can You Smoke Magic Mushrooms? appeared first on CBD Testers.

Banks and fintechs need to step up their game to serve customers better when it comes to money management.

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Vertiv Holdings Co (“Vertiv” or the “Company”) (NYSE: VRT) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Vertiv investments […]

The post Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Vertiv Holdings Co (VRT) on Behalf of Investors appeared first on Fintech News.

FinTech Futures speaks to DonateStock co-founder and chairman Steve Latham.

Many people use cannabis to help them fall asleep. For some, it becomes the only way they can drift into the netherworld. For the longest time, I suffered from this condition as well, laying awake staring at the roof, counting the minutes go by. Cannabis helped me tremendously during the hardest parts of my insomnia ridden years, but it was not the only thing that helped me eventually get to a point where I could pass out without the need of any substance.

When it's finally time to harvest, at least 60% of the trichomes on the crops will have turned milky white. You can confirm this coloration with a microscope. At the same time, you can check to see if the pistils have taken on a darker hue. These two methods are the best ways to determine if it's the optimal moment to harvest the plants.

Therefore, if you are within an age category that is plagued with side effects that cannabis can treat – then not making cannabis legal for this age group is illogical to say the least. Of course, this doesn’t mean that anyone within this age group would benefit from cannabis. Some people may have conflict with their current regimen of medicine – which is why it’s important that if you are within this age group, to consult your primary care physician about your plans to incorporate cannabis into your life.